Tetracaine Hydrochloride

Manufacturer
Bausch & Lomb Americas Inc. | Bausch & Lomb Incorporated
Effective date
2026-02-07
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
full-release
Hydrated at
2026-05-31 21:59:41

Label at a glance#

ProductTetracaine Hydrochloride
Active ingredientTETRACAINE HYDROCHLORIDE
Label structure15 sections

Indications and uses

Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic.

Dosage and administration

One drop topically in the eye(s) as needed.

Storage and handling

Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is supplied as a sterile, aqueous, topical ophthalmic solution in a low-density polyethylene plastic dropper bottle with a low-density polyethylene dropper tip and white polypropylene cap in the following sizes: NDC 82260-920-15       15 mL in a 15 mL Bottle  NDC 82260-920-05       5 mL in a 7.5 mL Bottle After opening, this product can be used until the expir...

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

One drop topically in the eye(s) as needed.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is a clear, colorless, ophthalmic solution containing 0.5% w/v tetracaine hydrochloride equivalent to tetracaine 0.44% w/v.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Corneal Injury with Intracameral Use

SPL UNCLASSIFIED SECTION

Not for injection or intraocular use. Do not use intracamerally because use of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% may lead to damage of the corneal endothelial cells.

5.2 Corneal Toxicity

SPL UNCLASSIFIED SECTION

Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage.

5.3 Corneal Injury Due to Insensitivity

SPL UNCLASSIFIED SECTION

Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.

5.4 For Administration by Healthcare Provider

SPL UNCLASSIFIED SECTION

Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is indicated for administration under the direct supervision of a healthcare provider. Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is not intended for patient self-administration [see  Warnings and Precautions (5.2)] .

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following serious ocular adverse reactions are described elsewhere in the labeling:

The following adverse reactions have been identified following use of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Ocular Adverse Reactions

Transient stinging, burning, and conjunctival redness, eye irritation, eye pain, ocular discomfort.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Risk Summary

There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature.

8.2 Lactation

LACTATION SECTION

Risk Summary

There are no data to assess whether Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is excreted in human milk or to assess its effects on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% and any potential adverse effects on the breastfed child from Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%.

8.3 Females and Males of Reproductive Potential

FEMALES & MALES OF REPRODUCTIVE POTENTIAL SECTION

No human data on the effect of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% on fertility are available.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Safety of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in the pediatric population has been demonstrated in clinical trials. Efficacy of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% for use in pediatric patients has been extrapolated from adequate and well-controlled clinical trials in the adult population.

8.5 Geriatric Use

GERIATRIC USE SECTION

No overall differences in safety or effectiveness of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% have been observed between elderly and younger patients.

10 OVERDOSAGE

OVERDOSAGE SECTION

Prolonged use of a topical ocular anesthetic including Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% may produce permanent corneal opacification and ulceration with accompanying visual loss.

11 DESCRIPTION

DESCRIPTION SECTION

Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is a sterile, clear, colorless, topical local anesthetic for ophthalmic use only containing tetracaine hydrochloride as the active pharmaceutical ingredient.

Tetracaine hydrochloride is chemically designated as benzoic acid, 4-(butylamino)-, 2-(dimethylamino) ethyl ester, monohydrochloride. Its chemical formula is C 15H 24N 2O 2● HCl and it is represented by the chemical structure:

CHEM
CHEM

Tetracaine hydrochloride is a fine, white, crystalline, odorless powder with a molecular weight of 300.83.

Active ingredient:tetracaine hydrochloride 0.5% w/v (equivalent to 0.44% w/v tetracaine)

Preservative:chlorobutanol 0.4%

Inactive ingredients:boric acid, edetate disodium dihydrate, potassium chloride, water for injection. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH (3.7 – 6.0).

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues.

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature.

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

Topical administration of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% results in localized temporary anesthesia. The maximum effect is achieved within 10–20 seconds after instillation, with efficacy lasting 10–20 minutes. Duration of effect can be extended with repeated dosing [see Warnings and Precautions (5.2)and Overdosage (10)] .

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is supplied as a sterile, aqueous, topical ophthalmic solution in a low-density polyethylene plastic dropper bottle with a low-density polyethylene dropper tip and white polypropylene cap in the following sizes:

  • NDC 82260-920-15       15 mL in a 15 mL Bottle 
  • NDC 82260-920-05       5 mL in a 7.5 mL Bottle

After opening, this product can be used until the expiration date stamped on the bottle.

Storage:Store at 15°C to 25°C (59°F to 77°F). Protect from light. Do not use if solution contains crystals, cloudy, or discolored.

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Eye Care Precaution

Do not touch the dropper tip to any surface as this may contaminate the solution.

Advise patients that, due to the effect of the anesthetic, their eyes will be insensitive for up to 20 minutes and that care should be taken to avoid accidental injuries.

Distributed by:
Bausch & Lomb Americas Inc.
Bridgewater, NJ 08807 USA

Manufactured by:
Bausch & Lomb Incorporated
Tampa, FL 33637 USA

© 2022 Bausch & Lomb Incorporated or its affiliates

9780400 (Folded)
9780500 (Flat)

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 15 mL carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC82260-920-15

Tetracaine
Hydrochloride
Ophthalmic
Solution, USP
0.5%
(Sterile)

FOR OPHTHALMIC USE

[EYE IMAGE]

Rx only

15 mL

BAUSCH + LOMB

9780301
MA09111

CARTON
CARTON

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1547771tetracaine HCl 0.5 % Ophthalmic SolutionPSN4
1547771tetracaine hydrochloride 5 MG/ML Ophthalmic SolutionSCD4
1547771tetracaine hydrochloride 0.5 % Ophthalmic SolutionSY4

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
TETRACAINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
9e37788c-b1bf-42ae-aac9-b60601606144Product name820260122
a26f29b9-6919-4f09-a354-491df8d2b97dProduct name120251021
1527ac37-808d-43be-a63e-74e1258dbe46Product name920250219
bed0530e-f939-4541-956b-6928a2f6404fProduct name120241008
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name620240814
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
9fcb7a91-de07-4f00-aabf-e4d6fda403d5Product name820230322
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
9badc7be-250a-44ab-aa36-926af3f02679Product name120210527
0ec3537a-6c9b-432a-896c-b9ea8723049aProduct name920200701
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
122d1fa8-7b9e-49b4-89ce-b062ffd1d947Product name120181030
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
7916de40-e296-41f0-b811-6d0df1a33e2cProduct name920180627
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name220171212
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
a993dfc5-f219-4460-bde6-30dd724d9ef0Product name120160818
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
4d7ae718-ed00-bae8-2abe-9eaec1eef7ffProduct name120140508
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
9137811f-f279-8640-5aeb-99fa2145d64dProduct name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
82260-920-05Tetracaine Hydrochloride5 mL in 1 BOTTLE, DROPPERSOLUTION/ DROPS54
82260-920-05Tetracaine Hydrochloride1 in 1 CARTONSOLUTION/ DROPS14
82260-920-15Tetracaine Hydrochloride15 mL in 1 BOTTLE, DROPPERSOLUTION/ DROPS154
82260-920-15Tetracaine Hydrochloride1 in 1 CARTONSOLUTION/ DROPS14

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
82260-920-05ML - Milliliter82260-9204e8715ca-5113-467e-a4f2-8040fa61bc6512025-10-14
82260-920-15ML - Milliliter82260-920f8e6c65f-1b0d-485f-ba22-3b2410b4267b12025-10-14

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
82260-92082260-920-05, 82260-920-15

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N210821-001TETRACAINE HYDROCHLORIDETETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-12

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
N210821-001AB1

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-1284e616aacf4f…
2026-08-18 06:07:402026-07N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-12caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-12011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-1231067a03dcf5…
2025-08-23 18:47 UTC2025-08N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-126a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-12fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-12b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICAB1RLD, RS2019-03-1203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-122680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-125bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-1279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-121e350fbaab3a…
2024-05-31 18:47 UTC2024-05N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-128072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-125c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-125d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-124b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMIC2019-03-1274a2ff9319b5…
2022-03-09 01:35 UTC2022-03N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-1287673890dc5c…
2021-03-12 10:30 UTC2021-03N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-125aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-128869cabd3fbd…
2020-11-12 02:37 UTC2020-11N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMIC2019-03-12c0c555d07b60…
2019-12-14 00:12 UTC2019-12N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMIC2019-03-123f01610625f2…
2019-09-15 20:21 UTC2019-09N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMIC2019-03-12b00525d2431f…
2019-07-19 19:46 UTC2019-07N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMIC2019-03-12ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-126a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-121c564ffb4f44…
2023-12-20 04:57 UTC2023-12N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-129b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-123f0d92c62455…
2023-05-13 08:27 UTC2023-05N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12053a50430f4f…
2023-01-26 05:58 UTC2023-01N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-123bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-123a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N210821-001TETRACAINE HYDROCHLORIDE0.5%SOLUTION / OPHTHALMICRLD, RS2019-03-12f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08N210821-001AB1184e616aacf4f…
2026-08-18 06:07:402026-07N210821-001AB11caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N210821-001AB11011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N210821-001AB1131067a03dcf5…
2025-08-23 18:47 UTC2025-08N210821-001AB116a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N210821-001AB11fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N210821-001AB11b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N210821-001AB1103ed91905a0d…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N210821-001AB11a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Tetracaine HydrochlorideTETRACAINE HYDROCHLORIDEBausch & Lomb Americas Inc.f12d5944-0d6c-43ff-89fd-e0b5669e9b4a2026-02-07Warnings, Adverse reactionsExact identifier
ndc (package): 82260-920-15
ndc (package): 82260-920-05
ndc (product): 82260-920
ndc11 (package): 82260092005
ndc11 (package): 82260092015
spl id: 4a468703-7613-0c8b-e063-6294a90a2f6e
spl set id: f12d5944-0d6c-43ff-89fd-e0b5669e9b4a

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.